Background: Rivastigmine and donepezil are both increase attention and working memory functioning. Objective: The purpose of the present study was to observe and compare the efficacy and safety of rivastigmine and donepezil in mild to moderate dementia. Methodology: This observational study was conducted on patients with mild to moderate dementia attended in the Out-patient
Introduction
Dementia is a clinical syndrome characterized by a loss of previously acquired intellectual function in the absence of impairment of arousal 1 between 75 and 84 and nearly half of those over 85 years of age 3 . The prevalence of questionable dementia was 11.5% and definite dementia was 3.6% 4 . At the primary and secondary levels of care, simple and brief assessment tools are more appropriate for assessment of severity of dementia, including the Mini-Mental State Examination (MMSE). The MMSE consists of several short cognitive probes, which are administered to the patient only. The results are summarized into a score that ranges from 30 (best) to zero (worst), spanning the spectrum from normal cognition to severe dementia. A large number of studies have demonstrated the reliability and validity of this instrument 5 , with mild cognitive impairment (MMSE scores of 21-26 inclusive), moderate cognitive impairment (MMSE scores of 10-20 inclusive) dementia and severe cognitive impairment MMSE scores of less than 10 6 . Reduced levels of Choline-acetyltransferase (ChAT) have been reported in patients with dementia 7 . Other researchers have reported that acetylcholine may have an important role in narrowing the scale of attentional focus 8 . Acetylcholinesterase Inhibitors (AChEIs) have used as 1st line treatment for memory problems in patients of dementia. The three common AChEIs available are donepezil, rivastigmine and galantamine. These AChEIs enhance cholinergic transmission by inhibiting acetylcholinesterase Inhibition activity to increase the availability of acetylcholine to interact with postsynaptic acetylcholine receptors. Although they have slightly different modes of action, their clinical efficacy is related primarily to the degree of inhibition. Donepezil is a specific and reversible inhibitor of acetylcholinesterase Inhibitors increasing the levels of synaptic acetylcholine thus improving cognitive functioning 9 . In contrast, rivastigmine is a pseudo-irreversible inhibitor of both acetylcholinesterase Inhibitors and butyrylcholinersterase (BuChE) inhibitor. Acetylcholinesterase selectively hydrolyses acetylcholine and is found mainly in the brain, whereas butyrylcholinersterase is a non-specific cholinesterase that hydrolyses many different choline-esters including acetylcholine and is found mainly at the periphery. The level of acetylcholinesterase is significantly decreased but that of BuChE increased in dementia patients 10 .This study is designed to observe and compare the effectiveness of rivastigmine and donepezil in the treatment of dementia.
Methodology
This descriptive type of observational study was conducted in Department of Pharmacology and Therapeutics in collaboration with Department of Neurology, Psychiatry and Medicine, Sylhet MAG Osmani Medical College Hospital, Bangladesh from July 2017 to June 2018 for a period of one year. All patients with mild to moderate dementia attending the outpatient departments of Neurology, Medicine and Psychiatry, fulfilling the inclusion criteria were considered as study population. Convenient consecutive sampling method was applied to select a total 230 sample of mild to moderate dementia of which 115 belonged to rivastigmine (Group-A) and another 115 belonged to donepezil (Group-B) for 12 weeks. Both quantitative and qualitative data were collected in a pre-designed questionnaire. Cognitive function was recorded using MMSE scale by measuring score of baseline, at the end of 4th and 12th week. Socio-demographic data such as age, sex, socio-economic status and educational level were recorded. Safety and tolerability assessments include monitoring and recording of all adverse events were defined as any undesirable sign, symptom or medical condition occurring in course of study period. Quantitative data were expressed as mean and standard deviation and comparison was performed between before and after measurement by paired t test or repeated measure ANOVA and between groups by unpaired t test. Qualitative data were expressed as frequency and percentages and comparison was performed between two groups by Fisher's exact test and Chi-Square test (test of association).Statistical analysis was performed by using SPSS (Statistical package for social science) for windows version 22.0. A probability value (p) of <0.05 was considered as significant.
Results
Two hundred and thirty (230) patients with mild to moderate dementia were selected from which 11 patients from group-A and 13 patients from group-B failed to complete study follow up visit were excluded. So, 104 patients of group-A (rivastigmine treated group) and 102 patients of group-B (donepezil treated group) were analyzed. The age of ranged of rivastigmine treated group was 50 to 80 years; while that of donepezil treated group ranged from 50 to 76 years. Mean ± SD age of rivastigmine and donepezil treated was 64.89 ± 6.82 and 63.67 ± 7.02 years respectively. The mean age of the both study groups did not differ significantly suggesting age matching study (t=1.274; p=0.204). In rivastigmine treated group, 36 (34.6%) patients were aged up to 60 years and 68 (65.4%) patients were above 60 years; it was 45 (44.1%) and 57 (55.9%) respectively in the donepezil treated group. There was no statistically significant difference between the age group of the patients between two treatment group (χ 2 =1.949; df=1; p=0.163) ( Table 1 ).
There were 45 (43.3%) male and 59 (56.7%) female in rivastigmine treated group; whereas 56 (53.9%) male and 46 (46.1%) female in donepezil treated group. The sex of the both study groups did not differ significantly suggesting sex matching study (χ 2 =2.339; df=1; p=0.126).The duration of dementia ranged from 3 to 48 months with the mean of 18.53 ± 9.25 months in group-A; whereas the duration of dementia in group-B ranged from 6 to 60 months with the mean of 20.82 ± 11.38 months. The duration of dementia in both treatment groups did not differ significantly (t=-1.589; p=0.114). In the rivastigmine treated group, the mean MMSE score was 14.39 ± 2.95 before the initiation of treatment which increased gradually to 16.37 ± 3.21 at the 4th week and to 19.95 ± 3.50 at the 12th week. The overall difference from the baseline to the end point of treatment was significant (F=284.156; df=2; p<0.001). In the donepezil treated group, the mean MMSE score was 15.05 ± 3.49 before the initiation of treatment which increased gradually to 15.84 ± 3.86 at the 4th week and to 19.19 ± 4.38 at the 12th week. The overall difference from the baseline to the end point of treatment was significant (F=107.427; df=2; p<0.001). When the changes the mean MMSE score were compared between two treatment groups, no significant difference was observed between rivastigmine treated group and donepezil treated group before initiation of treatment (t=-1.456; p=0.147), at 4 th week (t=1.056; p=0.292) and at 12 th week (t=1.388; p=0.166) ( Table 2 ).
This table also revealed that the reported adverse effects at 12 th week of treatment were nausea (2.9%), diarrhoea (2.9%) and dizziness (2.9%) in rivastigmine treated group; while the reported adverse effects were nausea (2.9%), vomiting (2.0%), diarrhoea (2.0%) and dizziness (3.9%) in donepezil treated group; the difference was not statistically significant between two treatment groups (p=0.779).
Discussion
Dementia is a syndrome that defies any simple definition; it has become a fear-laden term that encapsulates society's worst terrors. Despite the general lack of consensus about what dementia is in neurological terms, there is agreement that dementia is a long-term medical disability. To this end, there are regular reports in the media and elsewhere concerning the prevalence of the condition. In this study, the age of the patients ranged from 50 to 80 years with the mean age of 64.89 ± 6.82 years in rivastigmine treated group; whereas the age of the donepezil treated group ranged from 50 to 76 years with the mean age of 63.67±7.02 years. The mean age of the patients did not differ significantly between two treatment groups (p=0.204). This result was nearly similar to the study of parlayan et al 11 of which reported the average age for rivastigmine and donepezil groups was 68.9 ± 8.6 and 63.5 ± 6.4 years old, respectively. In this regards Bullock et al 12 found that mean age of the patients with probable Alzheimer's disease was 75.9 ± 6.6 years in rivastigmine treated group and 75.8 ± 6.8 years in donepezil treated group. Aguglia et al 13 showed mean age of the patients with probable Alzheimer's disease was years 78±6.4 years in rivastigmine treated group and 77 ± 6.47 years in donepezil treated group. Kazmierski et al 14 found the median age of the patients with probable Alzheimer's disease was 76 years in both rivastigmine and donepezil treated groups. The wide range of difference of age may be due to inclusion of probable Alzheimer's disease in those studies. But this study included both probable Alzheimer's disease and vascular dementia. These may be the cause of the difference. In this study 43.3% patients were male and 56.7% patients were female in rivastigmine treated group; whereas 53.9% patients were male and 46.1% patients were in donepezil treated group found in the present study. The sex of the patients of rivastigmine treated group and donepezil treated group did not show any statistically significant difference (p=0.126). Kazmierski et al 14 found that 38.71% of patients of rivastigmine treated group were male and 37.72% of patients of donepezil treated group were male; difference was not significant (p=0.74). Bullock et al 12 also showed similar gender distribution of their probable Alzheimer's disease patients that 31.1% male and 68.9% female in rivastigmine treated group; and 31.5% male and 68.5% female in donepezil treated group. Parlayan et al 11 found 50.0% male and 50.0% female in rivastigmine treated group; and 40.0% male and 60.0% female in donepezil treated group. Aguglia et al 13 reported, 34.0% male and 66.0% female inrivastigmine treated group and 36.0% male and 64.0% female in donepezil treated group. The duration of dementia in this study ranged from 3 to 48 months with the mean of 18.53 ± 9.25 months in rivastigmine treated group; whereas the duration ranged from 3 to 48 months with the mean of 20.82 ± 11.38 months in donepezil treated group. Both treatment groups showed almost similar (p=0.114) duration. In this regard Bullock et al 12 15 that patients taking rivastigmine, a statistically significant improvement (p=0.007) was found in MMSE result after 6 months of treatment. Similarly the patients taking donepezil also showed, a statistically significant improvement (p=0.04) in MMSE result after same duration of treatment.The present study showed that MMSE score was no significantly differences between rivastigmine and donepezil treated group before staring treatment (p=0.147); at 4 th week (p=0.292) and at 12 th week (p=0.166). This result was consistent with the study Abolfazli et al 15 that patients received rivastigmine and in patients took donepezil, MMSE score had reached higher score after 6 months but this difference between two drugs in improving MMSE score was not statistically significant. Bullock et al 12 and Touchon et al 16 also found no significant difference in improving MMSE between rivastigmine and donepezil treated patients. However Caffarra et al 17 showed a significant difference between donepezil and rivastigmine treated patients (p=0.03) with rivastigmine treated patients showing greater stability in MMSE scores than the donepezil group. The present study revealed that the reported adverse effects at 4 th week of treatment were nausea (11.5%), vomiting (2.9%), diarrhoea (2.9%) and dizziness (10.6%) in rivastigmine treated group; while the reported adverse effects were nausea (7.8%), vomiting (4.9%),diarrhoea (5.9%) and dizziness (6.9%) in donepezil treated group; the difference was not statistically significant between two treatment groups (p=0.551).Furthermore the reported adverse effects at 12 th week of treatment were nausea (2.9%), diarrhoea(2.9%) and dizziness (2.9%) in rivastigmine treated group; while the reported adverse effects were nausea (2.9%), vomiting (2.0%), diarrhoea (2.0%) and dizziness (3.9%) in donepezil treated group; the difference was not statistically significant between two treatment groups (p=0.779). Adverse effects reported in this study were mild and no discontinuation was needed. In this regards Aguglia et al 13 reported that the most common side effects were gastrointestinal in nature. They found diarrhoea 3(2.4%) versus 0(0.0%); nausea 1(0.8%) versus 1(1.4%); vomiting 1(0.8%) versus 0(0.0%); abdominal pain 0(0.0%) versus 1(1.4%); cardiovascular event 2(1.6%) versus 1(1.4%); hallucinations 0(0.0%) versus 1(1.4%); death while on treatment 3(2.4%) versus 9(12.8%) in rivastigmine and donepezil treated patients respectively. But Bullock et al 12 This difference may be due to difference in dose of the drugs they used in their studies. There are some limitations of this study. As this study was conducted in a single center tertiary hospital and did not represent the actual situation of the country. Sample size was small and duration of treatment period was short due to limitation of time. Only MMSE was employed in this study to assess the efficacy.
Conclusion
This study demonstrates that both rivastigmine and donepezil treatment appear to offer benefit in the treatment of dementia. But neither rivastigmine nor donepezil showed an advantage over each other on the primary outcome of cognitive function measured by MMSE. Both of these drugs are associated with a small number of side effects which are mild and needs no discontinuation. The differences between the two treatment regimens are not significant. Adverse effects of both treatment groups are not differed significantly.
